Jennifer R. Cochran
Publications
- Beyond antibodies: using biological principles to guide the development of next-generation protein therapeutics. Curr Opin Biotechnol. 2013
- Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin. Proc Natl Acad Sci U S A. 2011; (34): 14067-72
- Engineered epidermal growth factor mutants with faster binding on-rates correlate with enhanced receptor activation. FEBS Lett. 2011; (8): 1135-9
- Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists. Proc Natl Acad Sci U S A. 2011; (32): 13035-40
- Engineered proteins pull double duty. Sci Transl Med. 2010; (17): 17ps5
- Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinities. J Mol Biol. 2009; (4): 1064-75
- Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res. 2009; (6): 2435-42
- Interrogating and predicting tolerated sequence diversity in protein folds: application to E. elaterium trypsin inhibitor-II cystine-knot miniprotein. PLoS Comput Biol. 2009; (9): e1000499
- Developing therapeutic proteins by engineering ligand-receptor interactions. Trends Biotechnol. 2008; (9): 498-505
- Engineering agatoxin, a cystine-knot peptide from spider venom, as a molecular probe for in vivo tumor imaging. PLoS One. 2013; (4): e60498
- Diffusion of protein through the human cornea. Ophthalmic Res. 2012; (1): 50-5
- Cystine-knot peptides engineered with specificities for alpha(IIb)beta(3) or alpha(IIb)beta(3) and alpha(v)beta(3) integrins are potent inhibitors of platelet aggregation. J Mol Recognit.. 2011; (1): 127-35
- Discovery of improved EGF agonists using a novel in vitro screening platform. J Mol Biol. 2011; (2): 406-15
- Functional mutation of multiple solvent-exposed loops in the Ecballium elaterium trypsin inhibitor-II cystine knot miniprotein. PLoS One. 2011; (2): e16112
- PET Imaging of Integrin Positive Tumors Using F Labeled Knottin Peptides. Theranostics. 2011: 403-12
- Toward the development of an artificial cornea: improved stability of interpenetrating polymer networks. J Biomed Mater Res B Appl Biomater. 2011; (1): 8-17
- A Dual-Labeled Knottin Peptide for PET and Near-Infrared Fluorescence Imaging of Integrin Expression in Living Subjects. Bioconjug Chem. 2010
- Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin. J Nucl Med. 2010; (2): 251-8
- PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide. Cancer Res. 2010; (22): 9022-30
- Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J Nucl Med. 2010; (3): 433-40
- An engineered knottin peptide labeled with 18F for PET imaging of integrin expression. Bioconjug Chem. 2009; (12): 2342-7
- Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proc Natl Acad Sci U S A. 2009; (13): 5082-7
- Bioactive interpenetrating polymer network hydrogels that support corneal epithelial wound healing. J Biomed Mater Res A. 2009; (1): 70-81
- Engineered cystine knot peptides that bind alphavbeta3, alphavbeta5, and alpha5beta1 integrins with low-nanomolar affinity. Proteins. 2009; (2): 359-69
- Development of hydrogel-based keratoprostheses: a materials perspective. Biotechnol Prog. 2008 May-Jun; (3): 735-41
- Design and fabrication of an artificial cornea based on a photolithographically patterned hydrogel construct. Biomed Microdevices. 2007; (6): 911-22
- Elucidation of the interleukin-15 binding site on its alpha receptor by NMR. Biochemistry. 2007; (33): 9453-61
- Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast. Proteins. 2006; (4): 1026-35
- Improved mutants from directed evolution are biased to orthologous substitutions Protein Engineering, Design and Selection. 2006: 245-53
- Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. J Immunol Methods. 2004; (1-2): 147-58
- Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. J Mol Biol. 2004; (2): 539-50
- Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem. 2004; (29): 30375-84
- Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotechnol. 2003; (2): 163-70
- Soluble peptide-MHC monomers cause activation of CD8+ T cells through transfer of the peptide to T cell MHC molecules. Proc Natl Acad Sci U S A. 2002; (21): 13729-34
- Cutting edge: detection of antigen-specific CD4+ T cells by HLA-DR1 oligomers is dependent on the T cell activation state. J Immunol. 2001; (2): 741-5
- Receptor clustering and transmembrane signaling in T cells. Trends Biochem Sci. 2001; (5): 304-10
- Receptor proximity, not intermolecular orientation, is critical for triggering T-cell activation. J Biol Chem. 2001; (30): 28068-74
- T-cell activation by soluble MHC oligomers can be described by a two-parameter binding model. Biophys J. 2001; (5): 2547-57
- TCR: losing its inhibitions? Trends Immunol. 2001; (9): 479-80
- A diverse set of oligomeric class II MHC-peptide complexes for probing T-cell receptor interactions. Chem Biol. 2000; (9): 683-96
- The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligomers. Immunity. 2000; (3): 241-50
Help
Trial Administration